Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS

Acumen Pharmaceuticals — American Academy of Neurology 2024

5 slides from Acumen Pharmaceuticals's conference presentation, Apr 16, 2024

  1. Slide 1: A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes

    A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes Eric Siemers1, Erika Cline2, Todd Feaster1, Vladimir Skljarevski1, Karen Sundell1, Daniel Antwi- Berko3, Marleen Koel-

  2. Slide 2: INTERCEPT-AD: A Randomized Placebo Controlled Phase 1 Study in Early AD Patients

    INTERCEPT-AD: A Randomized Placebo Controlled Phase 1 Study in Early AD Patients COHORT 4: PART A: ≥ 1wk 60 mg/kg Sabirnetug SINGLE-ASCENDING DOSE or Placebo COHORT 3: n = 8 per cohort (32 total) 6:2 per cohort ≥ 1wk 25 mg/kg Sabirnetug or Placebo COHORT 2: ≥ 1wk 10 mg/kg Sabirnetug ≥ 1wk or Placebo

  3. Slide 3: INTERCEPT-AD: ARIA-E summary

    INTERCEPT-AD: ARIA-E summary 2 mg/kg 10 mg/kg 25 mg/kg 60 mg/kg Cohort 1 Cohorts 2, 5 Cohorts 3, 7 Cohorts 4, 6 ApoE D21 D140 ApoE D21 D140 ApoE D21 D140 ApoE D21 D140 3,4 3,4 PBO PBO 3,3 4,4 PBO PBO 3,3 PBO PBO 3,3 3,3 PBO PBO 3,4 SAD 3,4 2,3 3,3 3,4 4,4 3,3 3,4 3,3 PBO PBO 3,4 PBO PBO 3,4 PBO PBO

  4. Slide 4: Central Target Engagement (Sabirnetug-AβO Complex) Approaches Maximum at Highest Doses

    Central Target Engagement (Sabirnetug-AβO Complex) Approaches Maximum at Highest Sabirnetug Doses Administered in INTERCEPT-AD Single & Multiple Dose Cohorts - Exposure Response Relationship (Emax Model) 30 Sabirnetug-AβO Complex Target SAD 2 mg/kg Engagement SAD 10 mg/kg 20 SAD 25 mg/kg (AU/mL) SAD

  5. Slide 5: Sabirnetug-Associated Changes in CSF Biomarkers After 3 Administrations

    Sabirnetug-Associated Changes in CSF Biomarkers Indicate Downstream Pharmacology for Amyloid, pTau Species, and Synaptic Markers After 3 Administrations Ab 42/40 Ratio pTau181 pTau217 Improvement Worsening Worsening Worsening Improvement Improvement VAMP2 Neurogranin p= p= Worsening Worsening p= • n

Acumen Pharmaceuticals — American Academy of Neurology 2024 on 6ix